Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Operating expense | 39M | 16% |
| Net Income | -34M | 19.8% |
| EBITDA | -34M | 20.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 339M | 6.6% |
| Total Liabilities | 36M | 23.2% |
| Total Equity | 303M | 9.2% |
| Shares Outstanding | 43M | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -27M | 13.7% |
| Cash from financing | -150,000 | 73.3% |
EPS
Financial Highlights for Kyverna Therapeutics in Q3 '24
Operating Expenses for this period were 39M, showing a 16% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -34M, showing a -19.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -34M, showing a -20.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Kyverna Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
